Thibault, C <br/><br/>
Tumor-infiltrating lymphocytes can be activated in situ by using in vivo activants plus F(ab')2 bispecific antibodies.  [electronic resource] 

 -  International journal of cancer  Jul 1996 
 - 232-7 p.  digital 
<br/><br/> Publication Type: Journal Article; Research Support, Non-U.S. Gov't 
<br/><br/><label>ISSN: </label>0020-7136 
<br/><br/><label>Standard No.: </label>10.1002/(SICI)1097-0215(19960717)67:2<232::AID-IJC14>3.0.CO;2-D  doi 
<br/><br/><label>Subjects--Topical Terms: </label><br/>Animals<br/>Antibodies, Bispecific--pharmacology<br/>Cricetinae<br/>Cytotoxicity, Immunologic<br/>Enterotoxins--pharmacology<br/>Glucans--pharmacology<br/>Immunoglobulin Fab Fragments--pharmacology<br/>Lymphocyte Activation--drug effects<br/>Lymphocytes, Tumor-Infiltrating--immunology<br/>Melanoma, Experimental--immunology<br/>Mice<br/>Mice, Inbred C3H<br/>Neoplasm Transplantation<br/>T-Lymphocytes, Cytotoxic--immunology